Status: Not yet recruiting
A Phase III Study of SYHA1813 for Recurrent or Progressive High-Grade Meningiomas
This is a randomized, controlled, open-label, multicenter, Phase III clinical study designed to compare the efficacy and safety of SYHA1813 versus treatment of investigators' choice in patients with recurrent or progressive high-grade meningioma not amenable to local therapy.
Participants needed: 136
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Shanghai Runshi Pharmaceutical Technology Co., LtdUpdated: May 29, 2026
Eligibility criteria
1. Aged >= 18 years. [+7]
1. Individuals who are known to have severe allergic reaction to the study drug... [+16]